This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
Requests for original data may be submitted via e-mail to the corresponding author (shijumei@tongji.edu.cn).
References
Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10:8721–43.
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–34.
Gao M, Bai H, Jethava Y, Wu Y, Zhu Y, Yang Y, et al. Identification and characterization of tumor-initiating cells in multiple myeloma. J Natl Cancer Inst. 2020;112:507–15.
Lu S, Qian J, Guo M, Gu C, Yang Y. Insights into a crucial role of TRIP13 in human cancer. Comput Struct Biotechnol J. 2019;17:854–61.
Vader G. Pch2TRIP13: controlling cell division through regulation of HORMA domains. Chromosoma. 2015;124:333–9.
Wang Y, Huang J, Li B, Xue H, Tricot G, Hu L, et al. A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2020;80:536–48.
Tao Y, Yang G, Yang H, Song D, Hu L, Xie B, et al. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget. 2017;8:26718–31.
Li C, Xia J, Franqui-Machin R, Chen F, He Y, Ashby TC, et al. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Investig. 2021;131:e146893.
Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E, et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood. 2006;107:2170–9.
Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su Ihsin, Hannon G, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell. 2009;136:1122–35.
Avgustinova A, Benitah SA. Epigenetic control of adult stem cell function. Nat Rev Mol Cell Biol. 2016;17:643–58.
Shan Y, Liang Z, Xing Q, Zhang T, Wang B, Tian S, et al. PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs. Nat Commun. 2017;8:672.
Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B, et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature. 2021;589:448–55.
Acknowledgements
The authors thank the patients and healthy volunteers for their blood donations; The Myeloma Research Group of the Department of Hematology, Shanghai Tenth People’s Hospital for requesting patient consent and assisting with sample collection.
Funding
This work was supported by grants from the National Natural Science Foundation of China (Nos. 82170200, 81870158, 82070224, 81900207, 82000220, 81971529, and 22077131), Chinese Pharmaceutical Association-Yiling Biopharmaceutical Innovation Project (CPAYLJ201908).
Author information
Authors and Affiliations
Contributions
JS conceived and designed the research; JS, LX, YW, and WZ organized, analyzed and interpreted the data; LX, YW, GW, SG, DY, QF, KH, GC, XJ, HZ (Zhang), XG, HZ (Zhu) and JZ performed the experiments; SC, YL and HW provided key clinical specimens; XW, DS and GY performed the statistical analysis; JS and LX drafted the manuscript; BL, ZX, WZ, and FZ edited the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Xu, L., Wang, Y., Wang, G. et al. Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma. Leukemia 37, 1576–1579 (2023). https://doi.org/10.1038/s41375-023-01925-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-023-01925-w
This article is cited by
-
TRIP13 regulates progression of gastric cancer through stabilising the expression of DDX21
Cell Death & Disease (2024)
-
A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma
Scientific Reports (2024)